Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2020

Open Access 01-12-2020 | SARS-CoV-2 | Research Letter

Effect of favipiravir and an anti-inflammatory strategy for COVID-19

Authors: Hitoshi Yamamura, Hiroshi Matsuura, Junichiro Nakagawa, Hiroshi Fukuoka, Hisaya Domi, Satoru Chujoh

Published in: Critical Care | Issue 1/2020

Login to get access

Excerpt

Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent that selectively and potently inhibits the ribonucleic acid (RNA)-dependent RNA polymerase of RNA viruses [1]. In Japan, it is approved for use with novel influenza virus and is thought to be an effective drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) presents a complex pathology including inflammation, endothelial damage, thrombus formation, and acute respiratory failure [2‐4] This syndrome requires complex treatment to reduce viral genome amounts, anti-inflammatory drugs, and anticoagulation. We attempted the cocktail treatment of favipiravir, steroid, and heparin for COVID-19. This study aimed to evaluate the effect of cocktail therapy for severe COVID-19. …
Literature
1.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–63.CrossRef
2.
3.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.CrossRef
4.
Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region. Italy JAMA. 2020;323(16):1574–81.CrossRef
Metadata
Title
Effect of favipiravir and an anti-inflammatory strategy for COVID-19
Authors
Hitoshi Yamamura
Hiroshi Matsuura
Junichiro Nakagawa
Hiroshi Fukuoka
Hisaya Domi
Satoru Chujoh
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-020-03137-5

Other articles of this Issue 1/2020

Critical Care 1/2020 Go to the issue

Letter

First do no harm—beware the risk of therapeutic plasma exchange in severe COVID-19

Review

Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations

Research Letter

Identification of focal ARDS using PF ratio: a cross-sectional study

Research Letter

Duration of SARS-CoV-2 viral RNA in asymptomatic carriers

Letter

Naloxone should remain the appropriate antidote to treat opioid overdose

Research

Effect of withholding early parenteral nutrition in PICU on ketogenesis as potential mediator of its outcome benefit